Guangxi LiuYao Group Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guangxi Liuzhou Pharmaceutical Group Co., Ltd. (referred to as Liuzhou Pharmaceutical) is a regional pharmaceutical circulation enterprise. On December 4, 2014, the company was officially listed on the Shanghai Stock Exchange (stock abbreviation: Liuzhou Pharmaceutical, stock code: 603368). After more than 60 years of deep cultivation and meticulous work in the field of pharmaceutical circulation in Guangxi, Liuzhou Pharmaceutical has gradually formed a comprehensive pharmaceutical commercial business system with sales business of hospitals above designated size as the core, third-party terminal and pharmacy retail business as the wings, and commercial allocation and other businesses as supplements. Liuzhou Pharmaceutical is a designated unit for national pharmaceutical reserves and a business unit for drugs, anesthetics, and biological vaccines. It is one of the first enterprises in the region to pass the GSP certification. In 2015, the modern pharmaceutical logistics centers invested and constructed by Liuzhou Pharmaceutical in Liuzhou and Nanning passed the new version of GSP certification and were put into use. The company has been approved by the Autonomous Region Drug Administration to become one of the few pharmaceutical distribution enterprises in the region with modern logistics qualifications and third-party logistics qualifications. The establishment and operation of modern logistics centers in both regions will greatly improve the efficiency of enterprise distribution services, and also lay a solid foundation for enterprises to carry out new business models such as hospital modern logistics extension services, third-party logistics, and e-commerce. In the future, The company will continue to uphold The business philosophy of "integrity management and quality first" is to deeply cultivate and refine the market in the Guangxi region. Taking the historical opportunity of industry integration and market concentration improvement as an opportunity, we will continue to expand and strengthen our main business, accelerate the penetration and sinking of distribution networks and the implementation and operation of modern pharmaceutical logistics, and continuously improve the construction of marketing networks. Relying on advanced logistics equipment, information technology, and logistics management systems, we will effectively integrate marketing channels and upstream and downstream resources, and improve supporting services We will actively carry out hospital drug and consumable supply chain extension services, continuously increase market share, and achieve the transformation of enterprises from traditional single distribution providers to comprehensive modern pharmaceutical logistics service providers. Accelerate the implementation of traditional Chinese medicine slices production and processing projects and other drug production cooperation projects, while extending to downstream medical institutions, promoting cooperation in hospital investment, management, and information system platform research and development, bridging the entire industrial chain, achieving diversified development of enterprises, and consolidating and improving the company's leading position in the regional pharmaceutical commercial field. |
| Headquarter | Liuzhou |
| Establish Date | 12/23/1981 |
| Listed Code | 603368.SH |
| Listed Date | 12/4/2014 |
| Chairman | Zhu Chaoyang. |
| CEO | Zhu Chaoyang. |
| Website | www.lzyy.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
